RJFSA
AMED

Raymond James Financial Services Advisors’s Amedisys AMED Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,397
Closed -$413K – 3262
2022
Q1 		$413K Buy
2,397
+202
+9% +$30.2K ﹤0.01% 2493
2021
Q4 		$355K Buy
2,195
+41
+2% +$6.59K ﹤0.01% 2597
2021
Q3 		$321K Buy
+2,154
New +$448K ﹤0.01% 2648
2021
Q2 		– Sell
-3,358
Closed -$889K – 3305
2021
Q1 		$889K Sell
3,358
-98
-3% -$27.6K ﹤0.01% 1931
2020
Q4 		$1.01M Sell
3,456
-813
-19% -$208K ﹤0.01% 1692
2020
Q3 		$1.01M Buy
+4,269
New +$971K ﹤0.01% 1552
2019
Q2 		– Sell
-3,281
Closed -$404K – 2844
2019
Q1 		$404K Buy
3,281
+303
+10% +$38K ﹤0.01% 2026
2018
Q4 		$349K Buy
+2,978
New +$351K ﹤0.01% 1897

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Raymond James Financial Services Advisors's AMED Position: Q2 2022 in Review

Raymond James Financial Services Advisors sold out of Amedisys (AMED) in Q2 2022, closing a stake of 2,397 shares — an estimated $413K sold.

Raymond James Financial Services Advisors first reported a position in AMED in Q4 2018 and held it in 8 quarters. The position peaked at $1.01M in Q4 2020. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

  • Raymond James Financial Services Advisors reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 2,397 Amedisys shares in Q2 2022, an estimated $413K.
  • Raymond James Financial Services Advisors first reported a position in Amedisys in Q4 2018 and held it in 8 quarters.
  • Raymond James Financial Services Advisors's Amedisys position peaked at $1.01M in Q4 2020.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.